CD19-CAR-NK Cells therapy (ProCapZoom Biosciences)

N/A

Report date: 2025/11/24 20:00:49

Base Information

Drug NameCD19-CAR-NK Cells therapy (ProCapZoom Biosciences)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsNatural killer cell replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsMyasthenia Gravis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGuangdong ProCapZoom Biosciences Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGuangdong ProCapZoom Biosciences Co Ltd

Inactive CompaniesN/A

Active IndicationsMyasthenia Gravis

Inactive IndicationsN/A

Other Information

ATC CodeN/A